| Project/Area Number |
17K15510
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Kumamoto University |
|---|
Principal Investigator |
Oniki Kentaro 熊本大学, 大学院生命科学研究部(薬), 助教 (00613407)
|
|---|
| Research Collaborator |
SARUWATARI junji
JINNOUCHI hideaki
TSUJITA kenichi
OGATA yasuhiro
|
|---|
| Project Period (FY) |
2017-04-01 – 2019-03-31
|
| Project Status |
Completed (Fiscal Year 2018)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2018: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2017: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 糖尿病 / 肥満 / 非アルコール性脂肪性肝疾患 / モデリング / シミュレーション / DsbA-L / アディポネクチン / NAFLD / modeling & simulation / NONMEM |
|---|
| Outline of Final Research Achievements |
Disulfide-bond A oxidoreductase-like protein (DsbA-L) is a key molecule in the multimerization of adiponectin (i.e. activation of adiponectin). In the present study, we investigated the effects of the DsbA-L gene on the risk of life-style related diseases. We clarified the influence of the DsbA-L rs1917760 polymorphism on the adiponectin multimerization and the relationship of the polymorphism with the weight status using prediction models based on a non-linear mixed effect model among elderly participants of a health screening program. Moreover, we indicated that the DsbA-L rs1917760 polymorphism was associated with the risk of chronic kidney disease using prediction models based on a non-linear mixed effect model among patients with type 2 diabetes.
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究は、糖尿病に対する新規の予防・治療法の開発において、DsbA-Lが標的分子になり得ることを明らかにした知見であり、糖尿病の新規予防・治療法の開発に貢献するものである。また、本成果はモデリング&シミュレーションの手法を用いた独自の手法により、肥満や非アルコール性脂肪性肝疾患、糖尿病患者の慢性腎臓病に関する発症予測モデルの構築を試みた初めての知見でもあり、今後、様々な疾患への応用や医薬品の効果予測を組み込んだモデルへの拡張等、臨床での幅広い活用が期待される。
|
